LONGEVITY LATEST
The Evidence-Based Edge on Living Longer and Better
ISSUE #37 · 18 NOVEMBER 2026 · THE 9P RESULT
Morning Matcha, Daytime Hydration: Your Two-Drink Glow Routine
A warm matcha in the morning. B·T Fountain in cold water through the day. Pique's Radiant Skin Protocol turns two familiar moments into a daily beauty-from-within routine for hydrated-looking skin.
Sun Goddess Matcha is organic, ceremonial-grade matcha from Kagoshima, Japan, with naturally occurring caffeine and L-theanine for calm, sustained energy. B·T Fountain adds ceramides, hyaluronic acid and electrolytes to support skin moisture and a dewy-looking complexion.
Studies on the ceramides in B·T Fountain reported skin hydration improvements of up to 37% and elasticity improvements of up to 36% over two months.
Get 25% off all new subscriptions, plus free Holiday Chais on orders $80+, through November 29. Backed by a 90-day money-back guarantee.
Welcome
Nine pence. That’s what one tablet of nicotinamide, a plain form of vitamin B3, costs on the high street. In a phase 3 trial, people who’d had at least two non-melanoma skin cancers in five years took it twice a day and developed 23% fewer new ones during the year of treatment. Neither NR nor NMN, the NAD+ boosters selling from about £35 a month, has a phase 3 result like that.
This issue kept running into a pattern that’s worth stating as a question, not a rule. The positive NAD+ trials so far were in people with a specific medical problem; the nulls were mostly in healthy volunteers. None of the positive trials showed that a low NAD+ level was why it worked. And if you’re 35 to 60 and well, no trial yet shows a booster doing anything you’d feel, or that a health check would pick up.
Inside: seven claims graded, a year-long Parkinson’s trial in which placebo did slightly better, and a £799 Harrods drip.
SPOTLIGHT
Seven NAD+ claims, graded
Raises your NAD+ (NR, NMN)
A · the number only
Reliably. Both roughly double blood levels within two weeks.
Fewer repeat skin cancers (nicotinamide)
B · one group
During treatment, in people who’d had two or more. Untested in anyone else.
Walking with leg artery disease (NR)
C · one trial
One positive trial. Needs repeating at scale.
Muscle sugar uptake in prediabetes (NMN)
C · one small trial
One small positive trial. Nothing else in the blood moved.
Muscle and metabolism (no disease)
D · humans null
Pooled trials found no effect on muscle, strength, blood sugar or lipids.
Slowing early Parkinson’s (NR)
F · tested, failed
No benefit after a year. Placebo slightly ahead, below the threshold doctors count as meaningful.
NAD+ by IV drip
F · never tested
Never tested against placebo for any health outcome.
How to read the grades. A = consistent randomised trials; B = positive but few, small or narrow trials; C = mixed or preliminary; D = mostly lab and animal data; F = claims far outrun the data. The label after each grade says what kind of evidence it rests on: a blood number, a health outcome in one group, a trial that failed, or no trial at all. Each grade covers the named outcome only.
Christen et al. Nat Metab (2026) · Chen et al. (ONTRAC). N Engl J Med (2015) · McDermott et al. Nat Commun (2024) · Yoshino et al. Science (2021) · Prokopidis et al. J Cachexia Sarcopenia Muscle (2025) · Chen et al. Curr Diab Rep (2025) · NOPARK trial. JAMA (2026) · Grant et al. Front Aging Neurosci (2019)
THIS WEEK’S DEEP DIVE
Up Is Not the Same as Better
Does your NAD+ actually fall with age? Two 2026 blood studies, covering more than 1,300 people between them, say probably not.
One found blood levels flat across age groups; the other found them lower in people with heart disease and high blood pressure rather than in older people as such. The companion explains what that means for the number a home NAD+ test would give you, where boosting has helped, and the open safety question about one of B3’s breakdown products.
Read the companion: Up Is Not the Same as Better →
THIS WEEK’S ANALYSIS
Top 3 Interventions Under the Microscope
1. Nicotinamide for repeat skin cancers | Grade B
The good news: a cheap form of B3 has the best trial in the category.
Why it might work. UV light damages DNA in skin cells and can drain the energy they need to repair it. Nicotinamide feeds NAD+, which repair enzymes burn through, and in lab work it speeds up repair and blunts UV’s suppression of the skin’s immune defences. Think of it less as a youth pill and more as a refill for a crew working overtime.
The evidence. Australia’s ONTRAC trial gave 386 people, average age 66, who’d had at least two non-melanoma skin cancers in five years (eight on average) 500 mg twice daily or placebo for a year. New basal and squamous cell cancers fell 23% during treatment (95% CI 4 to 38), and precancerous patches by 11–20%. It was government-funded, with no supplement company behind it. Last year an observational study of 33,822 US veterans with past skin cancers linked nicotinamide use with about 14% fewer new ones: weaker evidence, same direction.
Where it stops. The benefit vanished within six months of stopping. In 158 organ-transplant patients, whose immune systems are suppressed, a 2023 trial found no benefit. Nobody has tested it in people who’ve never had skin cancer. It’s an option for one high-risk group to discuss with a dermatologist, alongside sun protection and skin checks, not instead of them.
Chen et al. (ONTRAC). N Engl J Med (2015) · Breglio et al. JAMA Dermatol (2025) · Allen et al. (ONTRANS). N Engl J Med (2023)
2. NR and NMN for muscle and metabolism | Grade D
This isn’t thin evidence. It’s evidence, and in healthy people it’s mostly null.
The trials. A 2025 review led by Konstantinos Prokopidis pooled 10 placebo-controlled trials of NMN or NR in people averaging 61 to 83: no effect on muscle mass, grip strength or walking speed. A separate review of eight NMN trials, 342 mostly healthy adults on 250–2,000 mg a day, found no change in fasting glucose, insulin, HbA1c or cholesterol. In September came the longest test yet: 62 over-65s in Tokyo on 1,250 mg of NMN for 24 weeks. NAD+ stayed raised; hearing, walking, blood markers and epigenetic age didn’t change. An NMN supplier funded it, which makes the null harder to wave away.
One exception. In 2021, 25 overweight women with prediabetes took 250 mg of NMN or placebo for 10 weeks at Washington University. Their muscle responded measurably better to insulin. Blood sugar, blood pressure, lipids and liver fat didn’t move. The study was NIH-funded, though one co-investigator receives patent-licensing fees, through the university, from two companies in the field. Small and narrow, but positive, in people whose metabolism was already slipping.
Prokopidis et al. J Cachexia Sarcopenia Muscle (2025) · Chen et al. Curr Diab Rep (2025) · Igarashi et al. npj Aging (2026) · Nutraceuticals World on Igarashi et al. (2026) · Yoshino et al. Science (2021) · Washington University release on Yoshino et al. (2021)
3. Nicotinamide riboside for early Parkinson’s | Grade F
The largest, longest test of an NAD+ booster in a brain disease. It failed.
What happened. After a 2022 pilot raised brain NAD+ in most of 30 patients, a Bergen team put 410 recently diagnosed people on 500 mg of NR twice daily or placebo for a year. Symptom scores rose 2.45 points on NR and dipped 0.27 on placebo: a gap of 2.72 in placebo’s favour (95% CI 0.47 to 4.98), below the trial’s own 5.2-point threshold for clinically important worsening. Non-motor symptoms worsened more on NR too.
I expected a null. I didn’t expect placebo to come out ahead.
What it means. Serious adverse events were rarer on NR (8.3% against 14.1%), so this isn’t evidence that NR harms healthy people. It is the clearest evidence yet that getting NAD+ into a tissue isn’t the same as fixing what’s wrong there. Some investigators hold NR patents licensed to Niagen Bioscience, which makes the result harder to dismiss.
HYPE CHECK
“Support your body’s normal NAD levels”
The claim. An NAD+ infusion straight into the vein, skipping the gut. REVIV’s clinic at Harrods lists one at £499 for 250 mg over two hours, or £799 for 500 mg over four, to “support your body’s normal NAD levels”.
The evidence. One published study has tracked what infused NAD+ does in human blood. During a six-hour drip, plasma NAD+ and its breakdown products didn’t change at all for the first two hours; the authors concluded the infused molecule was rapidly cleared. No trial has tested an NAD+ drip against placebo on anything you would book one for.
Nobody has shown a drip does more than a capsule. Two small studies found it rougher than an NR drip.
Why it misleads. Weigh both studies with their commercial ties in mind. In a 53-person trial funded by ChromaDex, which sells NR, NAD+ drips caused more and worse side effects and raised white cell counts. In a 2026 clinic review, all six NAD+ clients reported moderate to severe cramping, nausea or chest pressure, and sessions averaged 97 minutes as people slowed the drip. Neither measured a health benefit.
Our verdict. ❌ Not recommended. £799 buys about 20 months of daily NR capsules at UK prices, and even that buys you a number. Put the money into coached training instead, which has outcome evidence of its own (Issue 21).
REVIV at Harrods. Treatment list (2026) · Grant et al. Front Aging Neurosci (2019) · ChromaDex-funded IV trial, medRxiv preprint (NCT06382688) · Reyna et al. Front Aging (2026) · Healf. Tru Niagen 300 mg, 30 capsules (2026)
IN BRIEF
“Improved fatigue, sleep and depression.” So said an NR maker’s press release last November about a long COVID trial. Compared with what? Their own starting point. In the trial itself, 58 people took 2 g of NR a day for 20 weeks, or placebo for 10 weeks before switching to NR. Between the groups there were no significant differences on thinking, fatigue, sleep or mood, and only 18 of the 37 who started on NR finished. When a trial has a placebo group and the press release says “compared to baseline”, ask what happened to the placebo group.
Niagen Bioscience press release (2025) · Wu et al. eClinicalMedicine (2025) · Wu et al. trial registration (NCT04809974)
BIOHACKING CORNER · THE PLAN LIVES HERE
Train first, for what training is proven to do (Issues 21 and 35). Whether it also keeps muscle NAD+ up is unproven: one snapshot study found trained older adults close to the young, and exercise raised an NAD+-recycling enzyme in five small trials.
If you’ve had two or more non-melanoma skin cancers, ask your dermatologist about nicotinamide. That’s the group ONTRAC studied, at 500 mg twice daily; 90 tablets cost £7.95 at Holland & Barrett, about 18p a day. The label should say nicotinamide (or niacinamide), not niacin.
If you buy NR or NMN anyway, know what you’re buying: a higher blood number. They performed the same in a 65-person head-to-head, so there’s no reason to pay more for either.
Don’t combine B3 forms. They end up as the same breakdown products, and the Deep Dive explains why that question is still open.
Janssens et al. Nat Aging (2022) · iNAMPT exercise meta-analysis. Front Public Health (2023) · Chen et al. (ONTRAC). N Engl J Med (2015) · Holland & Barrett. NaturesPlus nicotinamide 500 mg, 90 tablets (2026) · Christen et al. Nat Metab (2026)
READER PULSE
Have you ever had an NAD+ IV drip? Reply to this email with Yes or No. We will review reader responses for a future edition.
If more than one in ten of you say yes, I’ll look at what these clinics test you for, including home NAD+ kits.
CLOSING
A grade I’m changing
In March, Issue 02 graded NR a B, mostly on the leg-artery trial. After NOPARK and this year’s null muscle trials, its case is narrower: that one result earns a C, and beyond raising the blood number, nothing else it’s sold for scores above a D. The test I’m waiting for is a trial in people first shown to be low in NAD+, such as frail older adults, with strength as the outcome. Next week: rapamycin, back from Issue 03 with new human trial data.
Stay curious and stay healthy!
Educational content, not personal medical advice. If you have Parkinson’s disease, the NOPARK researchers advise against NR or other NAD-boosting supplements outside clinical trials. Nicotinamide for skin cancer prevention was tested in people with at least two previous non-melanoma skin cancers; discuss it with your dermatologist or GP, especially if you have liver disease, take other medicines or have had an organ transplant. If you have cancer or a history of it, or are pregnant or breastfeeding, speak to your doctor before taking any NAD+ precursor. NAD+ drips are given by private clinics, not on the NHS, and side effects during infusion are common.
Reading notes
Evidence checked through 17 November 2026; each claim links to its source beside it. Grading rule this issue: D where support comes mainly from animals and human trials have been null; F where a claim is sold despite a failed or absent human test. ONTRAC’s primary outcome was the rate of new non-melanoma skin cancers over 12 months of treatment; basal and squamous cell results were secondary. The veterans study (Breglio et al., 2025) was a retrospective matched cohort of patients with prior skin cancer, mean age 77. ONTRANS stopped early after slow recruitment. Yoshino et al. measured muscle insulin sensitivity with a clamp in 25 postmenopausal women; secondary measures did not change. NOPARK: 410 randomised, 393 in the primary analysis; the 5.2-point clinically important worsening threshold is the trial’s own. Prokopidis et al. included adults with mean ages of 60.9 to 83 years. Igarashi et al. (npj Aging, 25 September 2026) was double-blind and placebo-controlled, with hearing as the primary outcome; trade-press coverage reports that Mirailab Bioscience funded it and supplied the NMN. The NICE trial (McDermott et al., 2024) used NR 1 g a day, reported its primary result with a one-sided 90% confidence interval, and listed ChromaDex among its funders. The IV comparison trial is a ChromaDex-funded preprint, not yet peer reviewed. The 2026 records review (Reyna et al.) covered six NAD+ and eight NR clients at one clinic, was funded by the clinic, and could not measure NAD+ levels. The long COVID trial randomised 37 people to NR throughout and 21 to placebo then NR; 18 completed in each arm; Niagen Bioscience was among its funders, and its reported improvements were within-group and post hoc. Issue 02 (10 March 2026) graded NR B, NMN D and niacin B−. Prices: REVIV at Harrods, Healf (£38.50 for 30 × 300 mg NR) and Holland & Barrett, November 2026.
Why are we so divided?
Mainstream media profits from "us vs. them" narratives, turning every story into a battle to keep you watching. 1440's unbiased newsletter delivers what actually happened, so you can stay informed without being manipulated.

